Loading
Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Most of the decisions on a non-muscle-invasive bladder cancer page (single instillation, BCG maintenance, early cystectomy, bladder-sparing trials) follow this guideline or its American counterpart.
Patients facing cystectomy for BCG-unresponsive disease have a bladder-sparing option, though most will eventually relapse and need close cystoscopic surveillance. The choice is a trade between keeping the bladder and the risk of progression while waiting.
Bladder-sparing gene therapy is a realistic option for BCG-unresponsive disease, given four times a year in clinic. Durability is limited and cystoscopic follow-up continues.
The risk groups that decide whether a patient gets a single chemotherapy instillation, BCG, or early cystectomy trace back to this work. Later models (CUETO, the 2021 EAU risk groups) refine the estimates for BCG-treated patients.
Query for this cancer: (TITLE:"Non-muscle-invasive bladder cancer" OR ABSTRACT:"Non-muscle-invasive bladder cancer" OR TITLE:"NMIBC" OR ABSTRACT:"NMIBC" OR TITLE:"Superficial bladder cancer" OR ABSTRACT:"Superficial bladder cancer" OR TITLE:"Ta, T1 and carcinoma in situ of the bladder" OR ABSTRACT:"Ta, T1 and carcinoma in situ of the bladder") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Non-muscle-invasive bladder cancer, not a curated reading list.